Prognostic value of cytokeratin 19 fragment (CYFRA 21-1) and cytokeratin-positive cells in bone marrow samples of breast cancer patients

International Journal of Biological Markers

Volumn 19, Issue 1, 2004, Pages 23-31

  Pierga, Jean Yves ^a   Deneux, L ^a   Bonneton, C ^a   Vincent Salomon, A ^a   Nos, C ^a   Anract, P ^b   Magdelenat H ^a   Pouillart, P ^a   Thiery, J P ^a  

^a INSTITUT CURIE   (France)

^b Cochin Hospital ^*  (France)

Author keywords

Circulating tumor cells; CYFRA 21 1; Cytokeratin; Prognosis

Indexed keywords

CYTOKERATIN 19 FRAGMENT; DIATRIZOATE; FICOLL; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; BONE MARROW METASTASIS; BREAST CANCER; CANCER CELL; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DENSITY GRADIENT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE TEST; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; SUPERNATANT;

EID: 1942519181     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.649     Document Type: Article

References (45)

1. Diel IJ, Kaufmann M, Costa SD, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996; 88: 1652-8.
2. Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 1999; 354: 197-202.
3. Funke I, Schraut W. Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. J Clin Oncol 1998; 16: 557-66.
4. Braun S, Muller M, Hepp F, Schlimok G, Riethmuller G, Pantel K. Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1998; 90: 1099-101.
5. Brugger W, Buhring HJ, Grunebach F, et al. Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. J Clin Oncol 1999; 17: 1535-44.
6. Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000; 342: 525-33.
7. Gebauer G, Fehm T, Merkle E, Beck EP, Lang N, Jager W. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol 2001; 19: 3669-74.
8. Gerber B, Krause A, Muller H, et al. Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol 2001; 19: 960-71.
9. Franke WW, Schiller DL, Moll R, et al. Diversity of cytokeratins. Differentiation specific expression of cytokeratin polypeptides in epithelial cells and tissues. J Mol Biol 1981; 153: 933-59.
10. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982; 31: 11-24.
11. Moll R, Krepler R, Franke WW. Complex cytokeratin polypeptide patterns observed in certain human carcinomas. Differentiation 1983; 23: 256-69.
12. Bader BL, Magin TM, Hatzfeld M, Franke WW. Amino acid sequence and gene organization of cytokeratin no. 19, an exceptional tail-less intermediate filament protein. Embo J 1986; 5: 1865-75.
13. Brotherick I, Robson CN, Browell DA, et al. Cytokeratin expression in breast cancer: phenotypic changes associated with disease progression. Cytometry 1998; 32: 301-8.
14. Slade MJ, Smith BM, Sinnett HD, Cross NC, Coombes RC. Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer. J Clin Oncol 1999; 17: 870-9.
15. Stathopoulou A, Vlachonikolis I, Mavroudis D, et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 2002; 20: 3404-12.
16. Xenidis N, Vlachonikolis I, Mavroudis D, et al. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 2003; 14: 849-55.
17. Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 1993; 53: 61-6.
18. Yamamoto K, Oka M, Hayashi H, Tangoku A, Gondo T, Suzuki T. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer 1997; 79: 1647-55.
19. Goumas PD, Mastronikolis NS, Mastorakou AN, Vassilakos PJ, Nikiforidis GC. Evaluation of TATI and CYFRA 21-1 in patients with head and neck squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec 1997; 59: 106-14.
20. Nakata B, Ogawa Y, Ishikawa T, et al. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer 2000; 89: 1285-90.
21. International Union Against Cancer. Breast tumours. In: Sobin LH, Wittekind C, eds. TNM classification of malignant tumours, 5th edition. New York: John Wiley and Sons, 1997; 123-30.
22. Pierga JY, Bonneton C, Magdelénat H, et al. Clinical significance of proliferative potential of occult metastatic cells in bone marrow of patients with breast cancer. Br J Cancer 2003; 89: 539-45.
23. Bauer KD, de la Torre-Bueno J, Diel IJ, et al. Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging. Clin Cancer Res 2000; 6: 3552-9.
24. Borgen E, Naume B, Nesland JM, et al. Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. Establishment of objective criteria for the evaluation of immunostained cells. The European ISHAGE Working Group for Standardization of Tumor Cell Detection. Cytotherapy 1999; 1: 377-88.
25. Ku NO, Liao J, Omary MB. Apoptosis generates stable fragments of human type I keratins. J Biol Chem 1997; 272: 33197-203.
26. Omary MB, Ku NO, Liao J, Price D. Keratin modifications and solubility properties in epithelial cells and in vitro. Subcell Biochem 1998; 31: 105-40.
27. Sheard MA, Vojtesek B, Simickova M, Valik D. Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. J Cell Biochem 2002; 85: 670-7.
28. Gion M, Boracchi P, Dittadi R, et al. Quantitative measurement of soluble cytokeratin fragments in tissue cytosol of 599 node negative breast cancer patients: a prognostic marker possibly associated with apoptosis. Breast Cancer Res Treat 2000; 59: 211-21.
29. Bormer OP. From tissue polypeptide antigen to specific cytokeratin assays. Tumour Biol 1994; 15: 185-7.
30. Pantel K, Schlimok G, Braun S, et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993; 85: 1419-24.
31. Mehes G, Witt A, Kubista E, Ambros PF. Circulating breast cancer cells are frequently apoptotic. Am J Pathol 2001; 159: 17-20.
32. Gion M, Peloso L, Mione R, et al. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients. Cancer J 2001; 7: 181-90.
33. McLaughlin R, McGrath J, Grimes H, Given HF. The prognostic value of the tumor marker CA 15-3 at initial diagnosis of patients with breast cancer. Int J Biol Markers 2000; 15: 340-2.
34. Bast RC, Jr, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1865-78.
35. Rodriguez CA, Cruz JJ, Martin T, Gomez A, Olaverri A, Hernandez M. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer 2002; 95: 670-1; author reply 671.
36. Giovanella L, Ceriani L, Giardina G, Bardelli D, Tanzi F, Garancini S. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) an carcinoembryonic antigen (CEA). Clin Chem Lab Med 2002; 40: 298-303.
37. Hochtlen-Vollmar W, Gruber R, Bodenmuller H, et al. Occult epithelial tumor cells detected in bone marrow by an enzyme immunoassay specific for cytokeratin 19. Int J Cancer 1997; 70: 396-400.
38. Ruud P, Fodstad O, Hovig E. Identification of a novel cytokeratin 19 pseudogene that may interfere with reverse transcriptase-polymerase chain reaction assays used to detect micrometastatic tumor cells. Int J Cancer 1999; 80: 119-25.
39. Ko Y, Klinz M, Totzke G, Gouni-Berthold I, Sachinidis A, Vetter H. Limitations of the reverse transcription-polymerase chain reaction method for the detection of carcinoembryonic antigen-positive tumor cells in peripheral blood. Clin Cancer Res 1998; 4: 2141-6.
40. Weigelt B, Bosma AJ, Hart AA, Rodenhuis S, van 't Veer LJ. Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br J Cancer 2003; 88: 1091-4.
41. Ikeda N, Miyoshi Y, Motomura K, Inaji H, Koyama H, Noguchi S. Prognostic significance of occult bone marrow micrometastases of breast cancer detected by quantitative polymerase chain reaction for cytokeratin 19 mRNA. Jpn J Cancer Res 2000; 91: 918-24.
42. Lugo TG, Braun S, Cote RJ, Pantel K, Rusch V. Detection and measurement of occult disease for the prognosis of solid tumors. J Clin Oncol 2003; 21: 2609-15.
43. Wiedswang G, Borgen E, Karesen R, et al. Detection isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 2003; 21: 3469-78.
44. Naume B, Borgen E, Nesland JM, et al. Increased sensitivity for detection of micrometastases in bone- marrow/peripheral-blood stem-cell products from breast cancer patients by negative immunomagnetic separation. Int J Cancer 1998; 78; 556-60.
45. Witzig TE, Bossy B, Kimlinger T, et al. Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin Cancer Res 2002; 8: 1085-91.